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ABSTRACT
Background: Poststroke depression (PSD) is common after stroke; however, the relationship to
poststroke function is inconclusive. Our objectives were to 1) determine the relationship between
PSD at baseline (1 month poststroke) and function (12 weeks later) and 2) assess the impact of
depression improvement on 12-week function among those with depression at baseline.
Methods:We completed a secondary analysis of data from a cohort study of participants with and
without PSD. We used logistic regression to identify factors associated with 12-week functional
dependence for 1) all 367 participants and 2) the 174 participants with PSD.
Results: In the PSD cohort, 3 characteristics were found to be independently associated with
12-week dependence: increased medical comorbidity (odds ratio [OR] 1.10, 95% confidence
interval [CI] 1.02–1.22), increased stroke severity (OR 1.42, 95% CI 1.19–1.69), and increased
baseline depression severity (OR 1.13, 95% CI 1.03–1.23). Depression severity was signifi-
cantly different between those considered dependent and independent at 12 weeks (entire co-
hort, PHQ-9 7.31 vs 5.18, p 0.008; depressed cohort, PHQ-9 9.94 vs 7.27, p 0.019).
Conclusion:Among study participants with PSD, the severity of depression symptoms at baseline
was associated with dependence; however, our results are inconclusive as to whether improve-
ment of depression is independently associated with functional recovery at 12 weeks. Even if the
treatment and improvement of PSD does not directly influence functional recovery poststroke, it
is essential for PSD to be identified and treated due to its high symptom burden and association
with other negative health and social outcomes. Neurology® 2011;76:1000–1005
GLOSSARY
AIM  Activate-Initiate-Monitor; CI  confidence interval; CIRS  Cumulative Illness Rating Scale; DSM  Diagnostic and
Statistical Manual of Mental Disorders; MMSE  Mini-Mental State Examination; mRS  modified Rankin scale; NIHSS 
NIH Stroke Scale; OR odds ratio; PHQ-9 Patient Health Questionnaire; PSD poststroke depression.
Each year approximately 795,000 people in the United States sustain a stroke1 and approxi-
mately one-third of survivors develop poststroke depression (PSD).2 PSD is common and
associated with many negative consequences, including lengthened hospital stays, prolonged
recovery time, increased mortality, and impaired functional outcomes.3-7
Several studies have reported that stroke survivors with PSD or depressive symptoms may
demonstrate worse functional outcomes, impairment, and recovery compared to those without
depression.3,4,8,9 Although many studies have linked PSD to worse functional outcomes, there
is little known about the impact of PSD treatment and improvement on function after stroke.
A recent Cochrane review of interventions for preventing PSD included only 14 PSD interven-
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tion trials.10 Results indicated no evidence
that PSD treatment had a positive impact on
cognition, function, or reduction of post-
stroke disabilities.
Care management of PSD, including
guideline-adherent use of antidepressants, has
been shown to significantly improve rates of de-
pression remission, compared to usual post-
stroke care.11 Whether this improvement in
depression is associated with concomitant im-
provement in function is not well-understood.
The objectives of this study were to 1) deter-
mine the relationship between PSD at baseline
(1 month after stroke) and functional outcomes
(12 weeks after baseline enrollment) and 2) as-
sess the impact of depression improvement on
12-week postenrollment functional recovery
among those who screened positive for depres-
sion at baseline.
METHODS Design. This was a secondary analysis of data
collected as part of the Activate-Initiate-Monitor (AIM) study.11
The AIM study included a randomized clinical intervention trial
nested within a cohort study. Stroke survivors were identified in
the inpatient setting. Those with depression were randomized at
1–2 months poststroke to either a depression care management
intervention group or usual care group. Nondepressed stroke
survivors were matched by site and time of enrollment (1–2
months poststroke) to depressed subjects. All subjects were pro-
spectively assessed with depression, stroke severity, function, and
other assessments at baseline (1–2 months poststroke) and at 12
weeks postenrollment. Thus all study participants were assessed
at approximately the same time points.
We utilized data from both the depressed and nondepressed
subjects to evaluate the impact of PSD on functional outcomes
poststroke. To assess the impact of depression treatment on
functional outcome, we analyzed data from the subjects with
depression only.
Participants. All study participants survived an ischemic
stroke, were more than 18 years old, were able to speak and
understand English, had a telephone, had no severe language or
cognitive impairments, and were expected to live at least 6
months. Subjects with prior or current depression treatment
were not excluded. Potential study subjects were identified at the
time of their stroke hospitalization. During recruitment, 1,175
consecutive patients from 4 hospitals were potentially eligible,
783 were excluded due to absence of depression, refusal to be in
the study, or a lack of follow-up for depression screening. While
still in the hospital, all potential subjects were invited to partici-
pate in depression screening 1 to 2 months poststroke for possi-
ble study enrollment. Patients who screened positive for
depression were further evaluated and were invited to enroll in
AIM if a diagnosis of major or minor depression was determined.
See the AIM article for further details and recruitment diagram.11
Standard protocol approvals, registrations, and patient
consents. The clinical trial identifier number for AIM is NCT
00029172. The AIM study article contains the flow chart of
participant recruitment for the trial.11 Human subjects approval
was received for the initial study and this secondary analysis. All
study participants consented.
Intervention. Those in the depression intervention group re-
ceived a care-management intervention including activation to
increase understanding and acceptance of the diagnosis of de-
pression, initiation of antidepressant medication, and monitor-
ing of the effectiveness of the medication for 12 weeks.11 Those
in the depression usual care group could receive antidepressant
treatment at the discretion of their provider. Any antidepressant
use during the 12 weeks was recorded during in-person assess-
ments at 12 weeks postenrollment.
Assessments. We collected demographic and clinical data at
baseline. Clinical data included cognition (validated 6-item ver-
sion of the Mini-Mental State Examination [MMSE]12) and
medical comorbidities (assessed with the Cumulative Illness Rat-
ing Scale [CIRS]13). The CIRS rates 13 body systems on a
4-point scale and was scored by trained chart abstractors using a
standardized tool.
Depression. Depression diagnosis at study entry was assessed
using the Patient Health Questionnaire (PHQ-9) as a screening
tool, followed by the Structured Clinical Interview for Depres-
sion for diagnosis.14,15 The PHQ-9 is validated for depression
screening in the poststroke population and includes 9 items as-
sessing 9 symptoms of depression as defined by the DSM.16,17
Depression improvement was defined as a decrease in PHQ-9
scores from baseline to 12 weeks of at least 50% or a 12-week
PHQ-9 score10.
Functional status. We measured functional status at baseline
and 12 weeks after baseline with the modified Rankin scale
(mRS), a categorical variable.18 It is a global overall measure of
functional status and does not focus solely on general or on in-
strumental activities of daily living. The mRS is scored 0–5: 0
no symptoms at all; 1  no significant disability despite symp-
toms: able to carry out usual duties and activities; 2  slight
disability: unable to carry out all previous activities but able to
look after own affairs without assistance; 3  moderate disabil-
ity: requiring some help but able to walk without assistance; 4
moderately severe disability: unable to walk without assistance,
and unable to attend to own bodily needs without assistance; and
5 severe disability: bedridden, incontinent, and requiring con-
stant nursing care and attention. Other studies have defined a
poor outcome (dependence) as a mRS2.19 Therefore, we spec-
ified the mRS as a dichotomous variable with 0–2 indicating
functional independence and 3–5 representing dependence after
stroke.19
Stroke severity. The NIH Stroke Scale (NIHSS) was used to
assess stroke severity.20 The NIHSS is an 11-item scale that in-
cludes consciousness, vision, language, sensory, and motor func-
tion. The NIHSS exhibits evidence of reliability and validity
with increasing scores representing increasing stroke severity. We
used the validated retrospective method of reviewing admission
physical examination records to assign a baseline NIHSS for each
subject.21
Statistical analysis. To determine the relationship between
PSD and functional outcome (12-week mRS score) after stroke,
we analyzed data from depressed and nondepressed study partic-
ipants (n  392); subjects were excluded from analysis if the
12-week mRS score was missing (n 25). There were no signif-
icant differences between those with and without a 12-week
mRS score. We used independent t tests and 2 analyses as ap-
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propriate to compare baseline demographics between those who
were and were not independent at 12 weeks postbaseline (mRS
2 vs 2). We examined the bivariate association between the
following variables and functional outcomes at 12 weeks: base-
line depression scores (PHQ-9), depression history, CIRS co-
morbidity index, stroke severity, age, gender, race, and
cognition. Variables associated with 12-week functional out-
comes in the bivariate analyses and those that were identified via
a priori clinical judgment (i.e., depression) were included in the
multivariate logistic regression model. Variables with a p 0.05
were kept in the final logistic regression model based on back-
ward selection of variables.
To assess the impact of depression improvement on post-
stroke functional recovery, we analyzed only subjects with de-
pression (n  174 of the 188 with PSD and with no missing
data). The above bivariate and multivariate analyses were re-
peated. Depression improvement was included in this second
logistic regression. The 6-item MMSE score was excluded from
both multivariate analyses as individuals required at least 4/6 to
be included in the study. NIHSS was included in the modeling,
regardless of the bivariate p value, in order to control for stroke
recovery.
The level of significance for terms to be kept in the final
model was set at p 0.05. No imputations were made for miss-
ing data; those without a 12-week mRS or PHQ-9 were ex-
cluded from the analysis. All analyses were completed using
SPSS statistical software, version 15.
Role of the funding source. The funding source had no
involvement or role in the collection, analysis, or interpretation
of the data, or in the writing of this manuscript or decision to
submit this manuscript for publication.
RESULTS The characteristics of the 367 included
individuals are found in table 1. The average age was
62 (12.7) years, 50% were male (n 182), and the
majority of participants were white (60%).
At 12 weeks postenrollment (4–5 months post-
stroke), 72 (20%) of the study participants were de-
pendent and 295 (80%) were independent.
Individuals dependent at 12 weeks were older (67 vs
61, p 0.001); had increased medical comorbidities
(CIRS, 16.6 vs 14.0, p  0.001); had increased
stroke severity (NIHSS, 3.58 vs 2.04, p  0.001);
and demonstrated decreased cognition (MMSE,
5.01 vs 5.45, p  0.001). There were no differences
in gender or race between those independent or de-
pendent at 12 weeks (p 0.94 and p 0.29, respec-
tively). Depression symptoms were not significantly
different by functional group at 12 weeks postbase-
line for the entire cohort.
The adjusted odds ratios (OR) and 95% confi-
dence intervals (95% CI) from the multivariable
analyses assessing factors associated with 12-week
functional outcomes are presented in table 2. Four
variables were included in the logistic regression: age,
comorbidity index, stroke severity, and baseline de-
pression. Three characteristics were independently
associated with decreased functional outcome (de-
pendence) at 12 weeks: increased baseline medical
comorbidity (OR 1.10, 95% CI 1.04–1.17), in-
creased NIHSS stroke severity (OR 1.36, 95% CI,
1.21–1.53), and increased age (OR 1.04, 95% CI,
1.02–1.07).
Table 3 shows the baseline characteristics for the
depressed only cohort (n  174). Those dependent
at 12 weeks postenrollment (n  35) had increased
baseline depression scores (15.8 vs 13.9, p  0.026)
than those independent at 12 weeks. Additionally,
we found 71% (122/173) of subjects with depression
met criteria for depression improvement (regardless
of treatment group). They were more likely to be
independent at 12 weeks when compared to those
who did not demonstrate depression improvement
(75% vs 53%, p  0.012).
Additionally, subjects in the depressed group who
were dependent at 12 weeks postenrollment were
older (64 vs 59, p 0.020), and demonstrated more
Table 1 Baselinecharacteristics inall strokesurvivorsaccordingtofunctional
statusat12weekspostenrollment
Variable
All study
participants
(n 367)
Independent at
12 weeks
(Rankin 0–2)
(n 295) (80%)
Dependent at
12 weeks
(Rankin 3–5)
(n 72) (20%) p Value
Age, y, mean SD 62 12.68 61 12.54 67 12.21 0.001
Male sex, n (%) 182 (50) 146 (50) 36 (50) 0.94
Race, n (%) 221 (60) 182 (62) 39 (54) 0.15
African American 136 (37) 104 (35) 32 (45) 0.29
White 221(60) 182 (62) 39 (54)
Other 10 (3) 9 (3) 1 (1)
Depression severity,
PHQ-9 score, mean SD
8.79 6.81 8.55 6.74 9.78 7.03 0.17
Depression history, n (%) 120 (33) 94 (32) 26 (37) 0.44
Medical comorbidity, CIRS
score, mean SD
14.51 5 13.99 4.92 16.58 4.84 0.001
Stroke severity, NIHSS
score, mean SD
2.34 2.26 2.04 1.99 3.58 2.82 0.001
Cognitive status, short
MMSE score, mean SD
5.37 0.852 5.45 0.79 5.01 1.00 0.001
Abbreviations: CIRS Comorbidity Index Rating Scale; MMSEMini-Mental State Exami-
nation; NIHSS  National Institutes of Health Stroke Scale; PHQ9  Patient Heath
Questionnaire–9.
Table 2 Independent baseline predictors of
dependency, full cohort
Variables contributing to
dependency (Rankin scores
3–5) at 12 weeks
Adjusted OR
(95%CI)
Age 1.04 (1.02–1.07)
Medical comorbidity, CIRS score 1.10 (1.04–1.17)
Stroke severity, NIHSS score 1.36 (1.21–1.53)
Abbreviations: CI  confidence interval; CIRS  Comorbid-
ity Index Rating Scale; NIHSS  National Institutes of
Health Stroke Scale; OR odds ratio.
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medical comorbidities (CIRS, 18.4 vs 15.8, p 
0.004), increased stroke severity (NIHSS, 3.94 vs
2.28, p 0.0001), and decreased cognition (MMSE,
4.91 vs 5.40, p  0.005).
The results from the second multivariable analysis
with the depressed only group are found in table 4.
We included age, CIRS, stroke severity, baseline de-
pression, and depression improvement into the
model. Three characteristics were found to be inde-
pendently associated with 12-week function in the
depressed group: increased baseline medical comor-
bidity (OR 1.10, 95% CI 1.02–1.22), increased
NIHSS stroke severity (OR 1.42, 95% CI 1.19–
1.69), and increased baseline PHQ-9 depression se-
verity (OR 1.13, 95% CI 1.03–1.23). Depression
response was significantly associated with depen-
dence at 12 weeks in the bivariate analysis, and there
was also a nonsignificant trend for this association in
the multivariate model (OR 0.60, 95% CI 0.25–
1.46).
We completed a post hoc exploratory analysis of
those who were dependent at baseline (n  92).
Comparing scores for the above variables, the follow-
ing were significantly different between those who
were independent (n 40) and dependent (n 52)
at 12 weeks: age (61 vs 67, p  0.01); medical co-
morbidities (CIRS, 14.67 vs 16.96, p  0.02); and
cognition (MMSE, 5.45 vs 5, p 0.05). This is par-
allel to our above analyses where we included both
those who were independent and dependent at base-
line; only NIHSS was not significantly different, but
this is due to everyone being dependent at baseline.
None of the variables were maintained in the multi-
variate modeling. We completed similar exploratory
analyses on the PSD-only cohort. For those with de-
pression who were dependent at baseline (n  56),
we found only medical comorbidities to be main-
tained in the predictive model (OR 1.21, 95% CI
1.04–1.42). There was a nonsignificant trend of
baseline depression being associated with 12-week
dependence (OR 1.08, 95% CI 0.96–1.24). How-
ever, it should be noted that sample size decreased
substantially to30 per group, allowing for the pos-
sibility of increased error.
In a second set of exploratory analyses, we exam-
ined the data from the PSD-only cohort. We in-
cluded treatment group (AIM intervention vs
control) and antidepressant use (regardless of treat-
ment group) to the logistic regression model (along
with the above variables: CIRS, NIHSS, PHQ-9);
neither variable independently predicted functional
status at 12 weeks. We also examined the association
of 12-week depression scores to functional outcome
in bivariate and multivariate analyses. In both the
entire cohort and the depressed cohort, there was a
significant difference in 12-week PHQ-9 scores be-
tween those who were dependent and independent at
12 weeks postenrollment (entire cohort, 7.31 vs
5.18, p 0.008; depressed cohort, 9.94 vs 7.27, p
0.019). When forced into the logistic regression
model, 12-week PHQ-9 scores, but not baseline
scores, were independently associated with 12-week
dependence for the entire cohort only (OR 1.06,
95% CI 1.01–1.11). The smaller sample size in these
analyses increases the probability of a Type II error in
this exploratory analysis.
DISCUSSION This study demonstrates that among
depressed and nondepressed stroke survivors, in-
creased age, more medical comorbidities, and base-
line stroke severity, but not baseline depression
Table 3 Baseline characteristics of depressed subjects according to
functional status at 12 weeks postenrollment
Variable
Depressed
subjects
(n 174)
Independent at
12 weeks
(Rankin 0–2)
(n 139) (80%)
Dependent
at 12 weeks
(Rankin 3–5)
(n 35) (20%) p Value
Age, y, mean SD 60.16 11.91 59.11 11.52 64.31 12.68 0.02
Male, n (%) 80 (46) 65 (47) 15 (43) 0.41
Race, white, n (%) 106 (61) 86 (62) 20 (57) 0.37
Race, n (%) 0.83
African American 62 (36) 48 (35) 14 (40)
White 106 (61) 86 (62) 20 (57)
Other 6 (3) 5 (4) 1 (3)
Depression severity,
PHQ-9 score, mean SD
14.28 5.20 13.89 5.38 15.80 4.14 0.026
Depression history, n (%) 86 (49) 69 (50) 17 (49) 0.91
Depression response, n (%) 122 (71) 104 (75) 18 (53) 0.012
Medical comorbidity, CIRS
total score, mean SD
16.30 4.85 15.77 4.78 18.37 4.63 0.004
Stroke severity, NIHSS score,
mean SD
2.61 2.48 2.28 2.32 3.94 2.67 0.001
Cognitive status, short MMSE
score, mean SD
5.30 0.91 5.40 0.84 4.91 1.07 0.005
Abbreviations: CIRS Comorbidity Index Rating Scale; MMSEMini-Mental State Exami-
nation; NIHSS  National Institutes of Health Stroke Scale; PHQ9  Patient Heath
Questionnaire–9.
Table 4 Independent predictors of
dependency, depressed cohort
Variables contributing to
dependency (Rankin scores
3–5) at 12 weeks
Adjusted OR
(95%CI)
Medical comorbidity, CIRS score 1.10 (1.02–1.22)
Stroke severity, NIHSS 1.42 (1.19–1.69)
Depression severity, PHQ-9 score 1.13 (1.03–1.23)
Abbreviations: CI  confidence interval; CIRS  Comorbid-
ity Index Rating Scale; NIHSS  National Institutes of
Health Stroke Scale; OR  odds ratio; PHQ9  Patient
Heath Questionnaire–9.
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symptoms, are independently associated with depen-
dence after stroke. Among those with PSD, baseline
depression severity, along with increased medical co-
morbidities and stroke severity, is independently as-
sociated with dependence after stroke. Although
depression improvement was associated with im-
proved functional outcome in the bivariate analysis,
this did not remain significant in the multivariable
model.
Previous studies have been inconsistent in their
findings regarding the association between post-
stroke depression and functional outcomes. Re-
searchers found depression was related to functional
impairment after stroke in people over the age of
65.22 Others have not found depression to be related
to functional outcomes after stroke.23,24
Time since stroke may be important when examin-
ing the relationship between depression and functional
recovery. Researchers have demonstrated that func-
tional outcomes related to depression may change dur-
ing the poststroke recovery time and that depression
may negatively impact the timing of functional recov-
ery.9,25 In this regard, we found 12-week depression se-
verity to be associated with dependence. However, due
to the cross-sectional nature of assessing depression se-
verity at the same time point that dependence was ascer-
tained, we cannot establish the directionality of the
association: dependence may have been the conse-
quence or the cause of depression at 12 weeks.
We also found cognition (MMSE) and neurologic
impairment (NIHSS) to be significantly related to func-
tion in the bivariate analysis. Recently, it was demon-
strated that antidepressant use was beneficial to
cognitive recovery when initiated during the first 3
months poststroke.26 This was regardless of change in
depression. Others have found that those with depres-
sion improvement demonstrated significantly better ac-
tivities of daily living functional improvement then
those without a remittance of depression.3,27 However,
timing of functional outcomes changes are not well-
understood.3 Our outcomes were assessed at 4–5
months poststroke; perhaps additional functional re-
covery would be foundwith continued depression treat-
ment over a longer period of time.
Of additional note, this trend of lower depression
scores with 12-week dependence is maintained when
we included only those with baseline depression and
dependence. Otherwise, only comorbidities were
found to be predictive of 12-week dependence. It is
likely that our small sample size of less than 30 is too
small for predictive modeling. Further research re-
garding those considered dependent at baseline or
directly after the stroke is necessary. Functional re-
covery and outcomes may be impacted by different
variables for individuals functioning at a higher level
during the earlier phases of poststroke recovery.
Finally, our models in the PSD cohort that in-
cluded treatment group (AIM intervention vs con-
trol) and antidepressant use (regardless of treatment
group) found neither variable independently pre-
dicted function at 12 weeks postenrollment. De-
pressed subjects who demonstrated depression
improvement had better functional outcomes at 12
weeks (approximately 4–5 months poststroke).
There was a trend for this association between de-
pression improvement and less dependence (OR
0.60, 95% CI 0.25–1.46) in the multivariate model,
though the CIs were wide and included 1.0. The few
participants in the PSD cohort who also were depen-
dent at 12 weeks (n 35) limits our power to detect
this association. Other authors have found functional
recovery to be related to remission of PSD23,28 but in
general, there is little research regarding the impact
of depression treatment on functional outcomes.
Possible explanations for this lack of association in
our study may be because not all intervention patients
had depression improvement and a number of control
patients did have depression improvement. A second
reason we may be limited in detecting this association is
the overall high level of function in the participants; at
12 weeks, 80% of the stroke survivors were classified as
independent.
Several other potential study limitations exist.
First, since the study participants had relatively mild
stroke, the mRS may not be sensitive enough to dis-
tinguish clinically important differences in func-
tional status in this cohort. This also affects the
generalizability of our findings to other older or more
impaired stroke cohorts. Future research should fo-
cus on people considered to be dependent directly
after stroke. We also excluded those with severe lan-
guage or cognitive impairments. Additionally, we
were not able to determine cause and effect between
depression and function; function may predict de-
pression and depression may predict function. Fi-
nally, only 35 participants were depressed and
dependent in functioning, thus limiting the power of
our trial to examine the independent effect of depres-
sion treatment on a secondary outcome such as func-
tional recovery.
Our data demonstrated that among the subset of
patients with PSD, the severity of depression symp-
toms is associated with functional outcome. Our
study is inconclusive as to whether improvement of
depression is independently associated with func-
tional recovery at 12 weeks. Even if the treatment
and improvement of PSD does not directly influence
functional recovery in all stroke survivors, it is essen-
tial for PSD to be identified and treated due to its
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high symptom burden and association with other
negative health and social outcomes. Further research
exploring whether PSD treatment is related to func-
tional recovery in a more heterogeneous and larger
group of stroke survivors is necessary to help identify
other mechanisms to improve stroke survivors’
outcomes.
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